Oncotelic Therapeutics, INC 8-K filings

Oncotelic Therapeutics has entered into a Securities Purchase Agreement with Pacific Pier Capital II, LP, issuing a convertible promissory note for $178,410 and commitment shares.

Oncotelic Therapeutics, Inc. filed an 8-K report detailing a corporate presentation given to employees, directors, officers, and advisors on July 13, 2026.

Oncotelic Therapeutics announced the grant of 17,796 Restricted Stock Units (RSUs) to directors, officers, employees, and advisors, tied to a stock exchange uplisting.

Oncotelic Therapeutics, Inc. has entered into a Securities Purchase Agreement with Pacific Pier Capital II, LP, issuing a convertible promissory note and commitment shares to raise $178,410.

Oncotelic Therapeutics, Inc. announced the completion of a merger involving its subsidiary Oncotelic Inc. and Lunai Bioworks, Inc., resulting in the acquisition of significant intellectual property assets.

Oncotelic Therapeutics reported a $249 million net income for fiscal year 2025, driven primarily by a non-cash fair value increase in its GMP Biotechnology joint venture investment.

Oncotelic Therapeutics has entered a joint development agreement with TechForce Robotics to commercialize an AI-enabled, GMP-compliant robotic system for pharmaceutical manufacturing.

Oncotelic announced that minority-held Sapu Nano will unveil its Deciparticle nanomedicine platform and two Phase 1 oncology candidates at BIO-Europe Spring 2026 on March 25.

Oncotelic Therapeutics, Inc. has entered into a securities purchase agreement with Mast Hill Fund, L.P., securing a $398,333.33 senior secured convertible promissory note and issuing warrants and commitment shares.

Oncotelic Therapeutics grants CEO Dr. Vuong Trieu up to 26,512 convertible Series A Preferred Stock shares tied to critical capital structure and market capitalization milestones.

Oncotelic Therapeutics, Inc. amended agreements with its CEO and an independent contractor, significantly reducing the market capitalization milestone required for restricted stock awards.

Oncotelic Therapeutics, Inc. amended an independent contractor agreement, lowering a key market capitalization milestone from $100 million to $45 million for restricted stock awards to Jefferson Capital Ventures, LLC.

Oncotelic Therapeutics, Inc. announced the completion of the third and final tranche of its unit offering, raising capital through convertible notes and warrants.

Oncotelic Therapeutics completed a private placement, issuing 32 units of convertible notes and warrants to 21 accredited investors.

Oncotelic Therapeutics announced open access to its PDAOAI evidence-interrogation platform and a comprehensive TGFliterature corpus for researchers.

Oncotelic Therapeutics, Inc. completed the initial tranche of a private placement, issuing convertible notes and warrants to raise capital for its operations.

Oncotelic Therapeutics' CEO, Dr. Vuong Trieu, presented an investor corporate update at LD Micro, detailing strategic plans for a JV IPO, clinical development, and new technology platforms.

Oncotelic Therapeutics, Inc. has entered into agreements with Jefferson Capital Ventures and Valor Nation for strategic consulting services aimed at boosting market capitalization, shareholder equity, and achieving a national exchange uplisting.

Oncotelic Therapeutics, Inc. has entered into a convertible promissory note agreement for $560,000 and an equity purchase agreement for up to $25 million with Mast Hill Fund, LP.

Oncotelic Therapeutics reports successful completion of a Phase 1 clinical trial of OT-101 combined with IL-2 for advanced or metastatic solid tumors, paving the way for further studies with checkpoint inhibitors.

Oncotelic Therapeutics and Mosaic ImmunoEngineering have extended the deadline for their potential reverse merger to June 30, 2025, to allow for further due diligence and agreement finalization.

Oncotelic Therapeutics has entered a binding term sheet to sell its necroptosis cancer therapy assets to Mosaic ImmunoEngineering for an initial $15 million in shares, with potential for an additional $30 million in cash and shares upon achieving milestones.

Oncotelic Therapeutics finalized the fourth tranche of its financing, issuing convertible notes and warrants, and converting $0.5 million of debt into equity.